2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2863

IgG Antiphospholipid Antibodies Enhance Stroke Damage: An in Vivo Ischemia/Reperfusion Study
Abstract Number: 1236

IgG4 Immunostaining Is Common but Not Specific in Orbitbal Inflammatory Diseases
Abstract Number: 2805

IgG4-Related Disease: Baseline Features in 100 Patients with Biopsy-Proven Disease
Abstract Number: 326

IL-1 Receptor Antagonis (IL-1Ra)-Fc Ameliorate Autoimmune Arthritis By Regulation of the Th17 Cells/Treg Balance and Arthrogenic Cytokine Activation
Abstract Number: 1915

IL-17 Gene Transfer induces Myeloid Precursor Cells That Initiate Epidermal Hyperplasia Independently of IL-23R⁺/CD4⁺ and γδ T Cells
Abstract Number: 1914

IL-17A Deficiency Promotes Periosteal Bone Formation in a Model of Inflammatory Arthritis
Abstract Number: 1042

IL-1β and TNF-α Promote Monocyte Viability through the Induction of GM-CSF Expression By Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1734

IL-22 Plays a Significant Role in the Initiation and Augmentation of Th17-Dependent Experimental Arthritis
Abstract Number: 1459

IL-22 Secreted By NKp44+NK Cells Promote the Proliferation of Synovium in Patients with Rheumatoid Arthritis By Activation of STAT3
Abstract Number: 1917

IL-23 Expression and Activation of Autophagy in Synovium and PBMCs of HLA-B27 Positive Patients with Ankylosing Spondylitis
Abstract Number: 632

IL-23 Mediates Psoriasis-like Inflammation in the SKG Mouse Model of Spondyloarthropathy
Abstract Number: 374

IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study
Abstract Number: 2801

IL-38: A New Factor in Rheumatoid Arthritis
Abstract Number: 1906

IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Abstract Number: 2455

IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].